Conditions: Healthy Volunteer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 99
Healthy volunteers: yes

Brief summary:
This multi-center, randomized, double-blind, multiple-dose, placebo-controlled, parallel-group study will assess the safety and PK of oseltamivir (Tamiflu) and its carboxylate metabolite, RO0640802 in healthy participants. Participants will be randomized to receive 100 milligrams (mg) oseltamivir, 200 mg oseltamivir, or placebo, all administered intravenously twice daily (BID). The anticipated time on study treatment is 5 days.

Detailed description:

Arms:
arm 1: Participants will receive 100 mg oseltamivir intravenous BID for 5 days. arm 2: Participants will receive 200 mg oseltamivir intravenous BID for 5 days. arm 3: Participants will receive oseltamivir matched placebo intravenous BID for 5 days.

Interventions: intervention 1: Oseltamivir intervention 2: Placebo
Intervention descriptions: intervention 1: Oseltamivir will be administered at 100 or 200 mg intravenous BID for 5 days. intervention 2: Oseltamivir matched placebo will be administered intravenous for 5 days.

Protocol document: